Glaukos Stock News

In the last trading session, 1.01 million shares of the Glaukos Corporation (NYSE:GKOS) were traded, and its beta was 1.68. Most recently the companys share price was $43.26, and it changed around $2.13 or 5.18% from the last close, which brings the market valuation of the company to $2.09B. GKOS currently trades at a discount Glaukos Corporation (NYSE: GKOS) Share Price Might Move Down By -36.39% Read More »

Taylor Frigon Capital Management LLC increased its position in shares of Glaukos Co. (NYSE:GKOS) by 57.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 108,478 shares of the medical instruments supplier’s stock after purchasing an additional 39,785 shares during the period. Glaukos accounts for 1.7% of Taylor Frigon Capital Management LLC’s investment […]

Glaukos Corporation (NYSE:GKOS) price on Friday, December 10, fall -3.10% below its previous days close as a downside momentum from buyers pushed the stocks value to $41.29. A look at the stocks price movement, the close in the last trading session was $42.61, moving within a range at $40.855 and $43.36. The beta value (5-Year Glaukos Corporation (GKOS) With A Potential Upside Of More Than -64.69% Read More »

Related Stocks: ZBH , PINS , HEI.A , LEVI , PNFP , G , ONON , DLTR , ZEN , TT , GKOS ,

Analysts expect that Glaukos Co. (NYSE:GKOS) will post sales of $67.60 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Glaukos earnings, with estimates ranging from $67.20 million to $68.40 million. Glaukos reported sales of $73.23 million during the same quarter last year, which would indicate a negative year []

Wall Street brokerages predict that Glaukos Co. (NYSE:GKOS) will announce earnings per share of ($0.35) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Glaukos earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.37). Glaukos reported earnings per share []

ICU Medical (NASDAQ:ICUI) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Valuation and Earnings This table compares ICU Medical and Glaukos top-line revenue, earnings per share (EPS) []

Wells Fargo & Company MN grew its position in shares of Glaukos Co. (NYSE:GKOS) by 12.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,880 shares of the medical instruments suppliers stock after purchasing an additional 9,443 shares during the period. Wells Fargo []

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

GKOS earnings call for the period ending November 29, 2021.

Wall Street analysts expect Glaukos Co. (NYSE:GKOS) to announce sales of $67.60 million for the current quarter, according to Zacks. Six analysts have made estimates for Glaukos earnings. The highest sales estimate is $68.40 million and the lowest is $67.20 million. Glaukos reported sales of $73.23 million in the same quarter last year, which would []

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d